AVROライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide...

Stats
本日の出来高	85 487.00
平均出来高	300 770
時価総額	53.61M
EPS	$0 ( 2024-03-28 )
次の収益日	( $-0.360 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	4.43
ATR14	$0.00500 (0.42%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-01	Golipour Azadeh	Sell	37 334	Restricted Stock Unit
2024-02-01	Golipour Azadeh	Buy	37 334	Common Stock
2024-02-05	Golipour Azadeh	Sell	12 232	Common Stock
2024-02-01	Ridha Essra	Sell	32 834	Restricted Stock Unit
2024-02-01	Ridha Essra	Buy	32 834	Common Stock

INSIDER POWER
54.77
Last 100 transactions
Buy: 6 327 240 \| Sell: 1 294 974

ボリューム相関

長: 0.09 (neutral)

短: 0.06 (neutral)

Signal:(50.569) Neutral

AVROBIO Inc 相関

10 最も正の相関
TLS	0.933
MBIN	0.909
HUBG	0.893
ALLK	0.892
PMBC	0.888
NBTB	0.884
ITOS	0.876
ATNX	0.873
CLOV	0.873
LTRX	0.871

10 最も負の相関
AAON	-0.865
DPCS	-0.861
GRPH	-0.851
BNIXU	-0.845
CINC	-0.844
SGEN	-0.842
IPAR	-0.841
XLNX	-0.829
RETA	-0.826
VCXA	-0.823

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

AVROBIO Inc 相関 - 通貨/商品

-0.77
( moderate negative )

-0.84
( strong negative )

0.00
( neutral )

0.84
( strong )

AVROBIO Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-617 000 (0.00 %)
EPS:	$0.270

FY	2023
収益:	$0
総利益:	$-617 000 (0.00 %)
EPS:	$0.270

FY	2022
収益:	$0
総利益:	$-4.17M (0.00 %)
EPS:	$-2.42

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.78

Financial Reports:

No articles found.

AVROBIO Inc

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.